Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights

J E Martin; S Khalife-Hachem; T Grinda; M Kfoury; S Garciaz; F Pasquier; J Vargaftig; M Uzunov; A Belhabri; S Bertoli; S Cotteret; V Vergé; A Renneville; F Rosselli; I Antony-Debre; E Rouleau; F Salviat; O Caron; S Delaloge; P Pautier; G Etienne; C Recher; N Vey; S De Botton; A Leary; C Marzac; J B Micol

doi:10.1016/j.annonc.2021.04.015

Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights

Ann Oncol. 2021 Aug;32(8):1046-1048. doi: 10.1016/j.annonc.2021.04.015. Epub 2021 Jun 6.

Authors

J E Martin¹, S Khalife-Hachem¹, T Grinda², M Kfoury³, S Garciaz⁴, F Pasquier⁵, J Vargaftig⁶, M Uzunov⁷, A Belhabri⁸, S Bertoli⁹, S Cotteret¹⁰, V Vergé¹⁰, A Renneville¹¹, F Rosselli¹², I Antony-Debre¹¹, E Rouleau¹⁰, F Salviat¹³, O Caron¹⁴, S Delaloge¹⁴, P Pautier¹⁵, G Etienne¹⁶, C Recher⁹, N Vey⁴, S De Botton¹, A Leary¹⁷, C Marzac¹⁰, J B Micol¹⁸

Affiliations

¹ Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
² Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Department of Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
³ Department of Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; INSERM U981, Villejuif, France.
⁴ Institut Paoli Calmettes, Marseille, France; Cancer Research Center of Marseille, INSERM U1068, Aix-Marseille University, Marseille, France.
⁵ Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; INSERM U1287, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
⁶ Institut Curie, Paris, France.
⁷ Hopital Pitié-Salpêtrière, Paris, France.
⁸ Department of Oncology, Centre Leon Berard, Lyon, France.
⁹ Hematology Department, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
¹⁰ Department of Biology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
¹¹ INSERM U1287, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
¹² CNRS UMR9019, Gustave Roussy Institute, Université Paris-Saclay, Villejuif, France.
¹³ Department of Biostatistics, Université Paris-Saclay, Villejuif, France.
¹⁴ Department of Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Interception Program, Personalized Cancer Prevention Center, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
¹⁵ Department of Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
¹⁶ Institute Bergonie, Hôpital Haut-Leveque, Pessac, France.
¹⁷ Department of Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; INSERM U981, Villejuif, France; Interception Program, Personalized Cancer Prevention Center, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
¹⁸ Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; INSERM U1287, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Interception Program, Personalized Cancer Prevention Center, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: Jeanbaptiste.MICOL@gustaveroussy.fr.

PMID: 34107346
DOI: 10.1016/j.annonc.2021.04.015

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

DNA Repair
Female
Humans
Neoplasms* / drug therapy
Ovarian Neoplasms*
Poly(ADP-ribose) Polymerase Inhibitors / adverse effects
Poly(ADP-ribose) Polymerases

Substances

Poly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-ribose) Polymerases